Benzinga's Top #PreMarket Gainers

shares rose 45.54 percent to $38.00 in pre-market trading following the announcement of positive top line results for ITI-007 first Phase 3 trial.

shares jumped 14.15 percent to $82.92 in pre-market trading following confirmation of

proposal to acquire

.

gained 4.23 percent to $3.70 in pre-market trading after the company reported the start of Janssen Phase 2 clinical trial of imetelstat in myelofibrosis.

shares rose 5.91 percent to $114.42 in pre-market trading after the company confirmed that it has proposed to acquire SABMiller.

shares climbed 4.14 percent to $56.35 in pre-market trading on AB InBev proposal to acquire SABMiller. Altira owns a 28 percent stake in SABMiller.